SEROQUEL is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is currently under investigation for use in the treatment of bipolar depression.
"The depressive phase of bipolar disorder, which patients experience approximately three times as often as the manic phase, is associated with significant impairment in quality of life. Quality of life is of critical importance for patients with bipolar disorder because they often experience relationship and work problems," said Jean Endicott, Ph.D., professor of Clinical Psychology in the Department of Psychiatry at Columbia University and Chief of the Department of Research Assessment and Training at the New York State Psychiatric Institute. "These data from the BOLDER trial are important because they recognize that quality of life is a key dimension of treatment in bipolar disorder."
The BOLDER study, an eight-week, double-blind, placebo-controlled trial, assessed SEROQUEL 300 mg/day and 600 mg/day versus placebo for the treatment of depression in 542 patients with bipolar I and II disorders. Data presented today analyzed quality of life in these patients using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q SF), a 16 item, self-report survey that measures differences in the degree of enjoyment and satisfaction among groups of patients, as well as changes ov